NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free VSTM Stock Alerts $4.02 -0.10 (-2.43%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$4.02▼$4.5050-Day Range$4.02▼$13.1652-Week Range$4.00▼$15.18Volume4.00 million shsAverage Volume1.12 million shsMarket Capitalization$101.83 millionP/E RatioN/ADividend YieldN/APrice Target$26.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Verastem alerts: Email Address Verastem MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside559.2% Upside$26.50 Price TargetShort InterestHealthy3.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.16Based on 25 Articles This WeekInsider TradingSelling Shares$6,619 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.14) to ($3.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.96 out of 5 starsMedical Sector526th out of 931 stocksPharmaceutical Preparations Industry235th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerastem has only been the subject of 2 research reports in the past 90 days.Read more about Verastem's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.94% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently decreased by 1.90%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VSTM. Previous Next 2.9 News and Social Media Coverage News SentimentVerastem has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Verastem this week, compared to 2 articles on an average week.Search Interest15 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days.MarketBeat Follows6 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,619.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($4.14) to ($3.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 4.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verastem's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Verastem Stock (NASDAQ:VSTM)Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More VSTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VSTM Stock News HeadlinesMay 29 at 2:14 AM | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Pro Medicus Limited (OtherPMCUF), AdaptHealth (AHCO) and Verastem (VSTM)May 28 at 8:44 AM | americanbankingnews.comRoyal Bank of Canada Lowers Verastem (NASDAQ:VSTM) Price Target to $16.00May 28 at 8:04 AM | americanbankingnews.comVerastem (NASDAQ:VSTM) Rating Reiterated by HC WainwrightMay 26 at 3:04 AM | seekingalpha.comVerastem: Narrowed Market And Less Compelling Efficacy Warrant Rating DowngradeMay 26 at 3:04 AM | seekingalpha.comVerastem: A Shocking Drop On 'Positive' Data (Maintain Buy)May 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verastem Amidst Promising Clinical Data and Market Expansion PotentialMay 24, 2024 | finance.yahoo.comWomen get dismissed by doctors—and it’s led to devastating consequences for cancerMay 24, 2024 | markets.businessinsider.comBuy Rating on Verastem: Promising RAMP 201 Study Outcomes and Favorable Investment PotentialMay 24, 2024 | msn.comVerastem whipsaws after updates for cancer drug comboMay 24, 2024 | bizjournals.comOvarian cancer drug developer's stock cut in half after it files for FDA approvalMay 24, 2024 | finance.yahoo.comSector Update: Health Care Stocks Advance Pre-Bell FridayMay 24, 2024 | finance.yahoo.comWhat's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?May 24, 2024 | investorplace.comWhy Is Verastem (VSTM) Stock Down 62% Today?May 24, 2024 | businesswire.comHarvest ETFs announces May 2024 DistributionsMay 24, 2024 | businesswire.comVerastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian CancerMay 24, 2024 | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from AnalystsMay 23, 2024 | businesswire.comVerastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and ...May 23, 2024 | msn.comVerastem shares surge more than 50% after pancreatic-cancer treatment study dataMay 23, 2024 | msn.comVerastem stock rallies on positive data for pancreatic cancer drug comboMay 23, 2024 | businesswire.comVerastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic CancerMay 21, 2024 | americanbankingnews.comVerastem (NASDAQ:VSTM) Stock Price Crosses Above 200-Day Moving Average of $10.14May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verastem Amid Positive Developments and Strong Financial PositionMay 13, 2024 | markets.businessinsider.comBuy Rating on Verastem: Promising Pipeline and Regulatory Milestones Drive Positive OutlookMay 10, 2024 | markets.businessinsider.comVerastem Inc. Poised for Growth: Buy Rating Affirmed on Clinical and Regulatory MilestonesMay 10, 2024 | investorplace.comVSTM Stock Earnings: Verastem Beats EPS for Q1 2024See More Headlines Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/28/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees73Year FoundedN/APrice Target and Rating Average Stock Price Target$26.50 High Stock Price Target$36.00 Low Stock Price Target$16.00 Potential Upside/Downside+616.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-157.95% Return on Assets-65.83% Debt Debt-to-Equity Ratio1.60 Current Ratio4.40 Quick Ratio4.40 Sales & Book Value Annual Sales$2.60 million Price / Sales39.16 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book1.77Miscellaneous Outstanding Shares25,330,000Free Float24,769,000Market Cap$101.83 million OptionableOptionable Beta0.58 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Daniel W. Paterson (Age 63)President, CEO & Director Comp: $697.98kMr. Daniel Calkins (Age 36)CFO and Principal Accounting & Financial Officer Comp: $1.42MMr. Richard H. Aldrich M.B.A. (Age 70)Founder and Consultant Comp: $38.39kDr. Robert A. Weinberg Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Piyush B. Gupta Ph.D.Co-FounderDr. Michelle Dipp M.D. (Age 48)Ph.D., Co-Founder Mr. Robert Pintar M.B.A.Senior Vice President of Technical OperationsDr. Jonathan Pachter Ph.D. (Age 66)Chief Scientific Officer Comp: $238.18kMr. Nate SanburnSenior Vice President of Corporate Development & External EngagementDr. Hagop Youssoufian M.D. (Age 67)M.Sc., Ph.D., Head of Medical Strategy More ExecutivesKey CompetitorsEpizymeNASDAQ:EPZMLexicon PharmaceuticalsNASDAQ:LXRXVanda PharmaceuticalsNASDAQ:VNDAXOMANASDAQ:XOMAAgenusNASDAQ:AGENView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 10,678 shares on 5/10/2024Ownership: 4.587%Cannon Global Investment Management LLCBought 11,100 shares on 4/17/2024Ownership: 0.044%Daniel CalkinsSold 6 sharesTotal: $65.22 ($10.87/share)Daniel CalkinsSold 25 sharesTotal: $300.50 ($12.02/share)Daniel CalkinsSold 55 sharesTotal: $608.85 ($11.07/share)View All Insider TransactionsView All Institutional Transactions VSTM Stock Analysis - Frequently Asked Questions Should I buy or sell Verastem stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VSTM shares. View VSTM analyst ratings or view top-rated stocks. What is Verastem's stock price target for 2024? 6 analysts have issued twelve-month price targets for Verastem's stock. Their VSTM share price targets range from $16.00 to $36.00. On average, they expect the company's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 559.2% from the stock's current price. View analysts price targets for VSTM or view top-rated stocks among Wall Street analysts. How have VSTM shares performed in 2024? Verastem's stock was trading at $8.14 at the start of the year. Since then, VSTM shares have decreased by 50.6% and is now trading at $4.02. View the best growth stocks for 2024 here. When is Verastem's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our VSTM earnings forecast. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) released its quarterly earnings data on Thursday, May, 9th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by $0.10. When did Verastem's stock split? Verastem shares reverse split on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Amarin (AMRN) and Viking Therapeutics (VKTX). Who are Verastem's major shareholders? Verastem's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.59%) and Cannon Global Investment Management LLC (0.04%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VSTM) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.